Around 25% of COVID-19 ICU sufferers had detectable RNAemia – extreme acute respiratory syndrome coronavirus 2 RNA – throughout the first six days of admission to ICU.
The presence of RNAemia was a powerful predictor of 28-day mortality. RNAemia was detectable in 56% of deceased sufferers however in solely 13% of survivors.
LGALS3BP was recognized as a binding protein to the SARS-CoV-2 spike protein. Rising ranges of LGALS3BP within the lungs provided safety to cells from the dangerous results of the SARS-CoV-2 spike protein.
The identification of LGALS3BP as a possible antiviral protein is encouraging because the UK authorities launched an Antivirals Taskforce in April 2021 to search out efficient therapies that would forestall future waves of infections and restrict the impact of latest variants.
Professor Manu Shankar Hari, a NIHR Clinician Scientist primarily based at King’s College London and a Consultant in Critical Care Medicine at Guy’s and St Thomas’, stated: “We report that presence of detectable viral RNA in plasma or serum of COVID-19 patients is associated with increased risk of severe illness.
We also highlight a novel interaction with potential antiviral effect between the SARS-CoV-2 spike protein and a protein called galectin-3-binding protein.
Our research findings have two main implications. First, there is an unmet diagnostic technology need for near patient tests to identify presence of viral RNA in blood in COVID-19 patients. Second, our research potentially highlights an antiviral drug target, which is a priority area highlighted within the UK government’s launch of a COVID-19 antivirals Taskforce.”
Professor Manuel Mayr, British Heart Foundation Professor at King’s College London, stated: “As British Heart Foundation Professor I am delighted that we could join forces with our clinical colleagues to contribute to a better understanding of COVID-19.
This is the first time blood proteins with the ability to bind to the SARS-CoV-2 spike protein have been analysed thanks to the specialised equipment available in King’s British Heart Foundation Centre.”